Age and grade trends in prostate cancer (1974-2003) - A Surveillance, Epidemiology, and End Results registry analysis

被引:30
作者
Jani, Ashesh B. [1 ]
Johnstone, Peter A. S. [1 ]
Lialtvv, Stanley L. [2 ]
Muster, Vira A.
Brawley, Otis W. [3 ]
机构
[1] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA
[2] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2008年 / 31卷 / 04期
关键词
prostate cancer; epidemiology; grade; age;
D O I
10.1097/COC.0b013e3181637384
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Age and pathologic grade are 2 critical factors used to guide clinical decisions and comparative outcomes studies in prostate cancer. The objective of this investigation was to use the Surveillance, Epidemiology, and End Results (SEER) registry to examine time trends in age and grade. Methods: The SEER public-use registry was queried by year of diagnosis from 1974 to 2003 for age at diagnosis (40-49, 50-59, 60-69, 70-79, and 80+ years) and for pathologic grade [well differentiated (WD), moderately differentiated (MD), and poorly differentiated (PD) disease]. Results were tabulated by 5-year interval; a total of 455,170 patients were included in the analysis. Time-trends analyses were performed for age, for grade, and for age and grade simultaneously, in each case applying a multivariate chi(2) test. Five-year Cause specific survival (CSS) rates were also tabulated by age and grade. Results: Overall, there was a nonsignificant (P = 0.68) change in distribution of age tit diagnosis. However, a significant (P < 0.001) grade migration took place over the study period, principally from WD to MD disease, and Occurred across all age groups. Five-year cause Specific Survival time trends were similar for all age groups, but WD appeared to converge with MD disease in later years. Conclusions: An overall grade migration has occurred in prostate cancer, primarily observed as a shift from)WD to MD disease; this may weaken grade-based prognostic categorizations. This migration Occurred independent of patient age, reinforcing that the grade migration is likely due to changes in pathologic interpretation rather than to screening-related changes in disease characteristics.
引用
收藏
页码:375 / 378
页数:4
相关论文
共 32 条
[1]   Prostate cancer and the Will Rogers phenomenon [J].
Albertsen, PC ;
Hanley, JA ;
Barrows, GH ;
Penson, DF ;
Kowalczyk, PDH ;
Sanders, MM ;
Fine, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1248-1253
[2]   20-year outcomes following conservative management of clinically localized prostate cancer [J].
Albertsen, PC ;
Hanley, JA ;
Fine, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17) :2095-2101
[3]  
APRIKIAN AG, 1994, CANCER, V74, P1768, DOI 10.1002/1097-0142(19940915)74:6<1768::AID-CNCR2820740620>3.0.CO
[4]  
2-9
[5]   Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma [J].
D'Amico, AV ;
Cote, K ;
Loffredo, M ;
Renshaw, AA ;
Chen, MH .
CANCER, 2003, 97 (01) :56-62
[6]  
DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS
[7]   Continuing trends in pathological stage migration in radical prostatectomy specimens [J].
Derweesh, IH ;
Kupelian, PA ;
Zippe, C ;
Levin, HS ;
Brainard, J ;
Magi-Galluzzi, C ;
Myles, J ;
Reuther, AM ;
Klein, EA .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (04) :300-306
[8]   Current practice of Gleason grading among genitourinary pathologists [J].
Egevad, L ;
Allsbrook, WC ;
Epstein, JI .
HUMAN PATHOLOGY, 2005, 36 (01) :5-9
[9]   Update on the Gleason grading system for prostate cancer - Results of an international consensus conference of urologic pathologists [J].
Epstein, JI ;
Allsbrook, WC ;
Amin, MB ;
Egevad, LL .
ADVANCES IN ANATOMIC PATHOLOGY, 2006, 13 (01) :57-59
[10]   National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening [J].
Farkas, A ;
Schneider, D ;
Perrotti, M ;
Cummings, KB ;
Ward, WS .
UROLOGY, 1998, 52 (03) :444-448